Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study
A Blauvelt, K Reich, TF Tsai, S Tyring… - Journal of the american …, 2017 - Elsevier
Background Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and
week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe
plaque psoriasis. Objective To compare the efficacy and safety of secukinumab and
ustekinumab use over 52 weeks. Methods Analysis of 52-week data from CLEAR, a
randomized, double-blind, phase 3b study. Results Among 676 randomized subjects,
secukinumab demonstrated superiority to ustekinumab at week 52 in the proportion of …
week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe
plaque psoriasis. Objective To compare the efficacy and safety of secukinumab and
ustekinumab use over 52 weeks. Methods Analysis of 52-week data from CLEAR, a
randomized, double-blind, phase 3b study. Results Among 676 randomized subjects,
secukinumab demonstrated superiority to ustekinumab at week 52 in the proportion of …